Changes to this Summary (01/28/2015)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Revised text to state that the molecular profile of pediatric patients with oligodendrogliomas rarely demonstrates deletions of 1p or 19q, as found in 40% to 80% of adult cases (cited Rodriguez et al. as reference 48).
Added Naftel et al. as reference 30.
Added text to state that bevacizumab has also been employed for children with low-grade gliomas and symptomatic radiation-induced tumor enlargement; it produced radiographic improvement and allowed weaning off steroids (cited Foster et al. as reference 70).
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.